The 25 highest-scored Biotechnology companies in the AskCyborg corpus, ranked by Cyborg Score — a 1–10 rating from a bull-vs-bear AI analyst debate across 11 dimensions. Each links to the full research report.
| # | Company | Cyborg Score | The verdict |
|---|---|---|---|
| 1 | COMPASS Pathways plc | 8/10 | Breakthrough clinical data combined with strong capital position creates compelling risk-reward for a first-in-class mental health therapeut |
| 2 | Eckert & Ziegler SE | 8/10 | Growth-stage isotope technology provider capturing secular tailwinds in precision oncology and nuclear medicine with demonstrated margin exp |
| 3 | Bavarian Nordic A/S | 8/10 | Essential vaccine supplier with dual-revenue-stream growth strategy, government contracts providing stability while travel health business a |
| 4 | Beam Therapeutics Inc. | 8/10 | Clinical-stage gene editing leader with modular platform, regulatory clarity on key programs, strong balance sheet, and clear execution path |
| 5 | Legend Biotech | 8/10 | Market-leading CAR-T franchise achieving profitability at scale with differentiated clinical data and manufacturing capacity advantage. |
| 6 | CG Oncology, Inc. | 8/10 | Leading oncolytic immunotherapy candidate in bladder cancer with strong clinical efficacy, multiple upcoming data catalysts in 2026, and 3+ |
| 7 | Cogent Biosciences, Inc. | 8/10 | Precision oncology player with compelling Phase 3 data and multiple 2026 NDA filings targeting rare, underserved diseases offers significant |
| 8 | Krystal Biotech, Inc. | 8/10 | Vyjuvek's commercial success and a robust catalyst-rich pipeline position Krystal for sustained growth. |
| 9 | Abivax SA | 8/10 | First-in-class anti-inflammatory molecule with blockbuster Phase 3 data in large IBD market with limited competition from novel mechanisms. |
| 10 | Novonesis | 8/10 | Market-leading biosolutions provider with strong growth potential and sustainability tailwinds, though integration execution risk remains. |
| 11 | CSL Limited | 8/10 | CSL is a resilient biotech leader with defensible market positions, recurring revenue streams, and strong execution capabilities well-positi |
| 12 | MindWalk Holdings Corp. | 7/10 | Proprietary Bio-Native AI platform with high-value pipeline in GLP-1, dengue vaccines, and neurodegeneration offers significant upside despi |
| 13 | Bioventix PLC | 7/10 | Specialized biotech with defensive characteristics offering attractive dividends and stable cash generation, suitable for dividend-focused p |
| 14 | XOMA Royalty Corporation | 7/10 | Unique non-dilutive biotech funding model with diversified 120+ asset portfolio and growing royalty revenue streams offers attractive risk-a |
| 15 | Benitec Biopharma Inc. | 7/10 | Emerging gene therapy player with differentiated ddRNAi platform and de-risked lead program, positioned to capture value in rare genetic dis |
| 16 | ProKidney Corp. | 7/10 | ProKidney offers a buy opportunity due to promising Phase 2 data for rilparencel in advanced CKD, strong FDA alignment, and sufficient cash |
| 17 | Nanobiotix S.A. | 7/10 | Nanobiotix is a physics-based cancer nanotherapy company with differentiated NBTXR3 in partnership with J&J, multiple 2026 clinical catalyst |
| 18 | Immunocore Holdings plc | 7/10 | First-to-market TCR therapy with expanding global commercialization and strong pipeline, but profitability depends on pipeline progression b |
| 19 | Recursion Pharmaceuticals, Inc. | 7/10 | AI-enabled drug discovery platform with differentiated pipeline and strategic partnerships, but success dependent on clinical trial outcomes |
| 20 | Wave Life Sciences Ltd. | 7/10 | Innovative RNA medicine platform with meaningful pipeline and strong partnerships, but execution risk typical of clinical-stage biotech rema |
| 21 | Arrowhead Pharmaceuticals, Inc. | 7/10 | Pioneering RNAi therapeutic company achieving first commercial approval milestone with strong cash position and validated Novartis partnersh |
| 22 | Iterum Therapeutics plc | 6/10 | Commercial validation of Orlynvah provides proof-of-concept for oral penems; sulopenem pipeline offers meaningful upside if Phase 3 data sup |
| 23 | Pieris Pharmaceuticals, Inc. | 6/10 | Early-stage biotech with differentiated Anticalin platform and promising 4-1BB bispecific pipeline attracting analyst optimism and partnersh |
| 24 | Xilio Therapeutics, Inc. | 6/10 | Innovative masked immuno-oncology platform with promising clinical data and adequate runway, but execution-dependent with meaningful binary |
| 25 | Annovis Bio, Inc. | 6/10 | Strong Buy consensus from analysts as of January 2026, supported by near-term clinical catalysts and potential disease-modifying efficacy in |
See also the Biotechnology rankings PDF and industry research.
Cyborg Scores (1–10) are synthesized by AskCyborg’s multi-agent analyst-debate framework across 11 dimensions, recalibrated weekly. Methodology · Scoring rubric.